Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Latigo Biotherapeutics(LTGO) the EBIT is -23.44 M (-8.94%);the EPS is -3.93 (+5.72%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.02B8.94%
----
----
EPS
-3.93245.72%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf